Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl] butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 573-585

  Sandanayaka, Vincent ^a   Mamat, Bjorn ^b   Mishra, Rama K ^a   Winger, Jennifer ^a   Krohn, Michael ^a   Zhou, Li Ming ^a   Keyvan, Monica ^a   Enache, Livia ^a   Sullins, David ^a   Onua, Emmanuel ^a   Zhang, Jun ^a   Halldorsdottir, Gudrun ^b   Sigthorsdottir, Heida ^b   Thorlaksdottir, Audur ^b   Sigthorsson, Gudmundur ^b   Thorsteinnsdottir, Margret ^b   Davies, Douglas R ^a   Stewart, Lance J ^a   Zembower, David E ^a   Andresson, Thorkell ^b   Kiselyov, Alex S ^a   Singh, Jasbir ^a   Gurney, Mark E ^a,b   more..

^a DeCODE Chemistry & Biostructures   (United States)

^b DECODE GENETICS   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [[4 (4 CHLOROPHENOXY)PHENOXY]METHYL] 1 PYRROLIDINYL]BUTANOIC ACID; DG 051; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME INHIBITION; HEART INFARCTION; HUMAN; NONHUMAN; STROKE; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL AVAILABILITY; BUTYRIC ACIDS; CARDIOVASCULAR DISEASES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HETEROCYCLIC COMPOUNDS; HUMANS; LIGANDS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; SOLUBILITY; STROKE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77249161707     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm900838g     Document Type: Article

References (59)

1. Helgadottir, A.; Manolescu, A.; Thorleifsson, G.; Jonsdottir, H.; Thorsteinsdottir, U.; Samani, N. J.; Gretarsdottir, S.; Johannsson, H.; Gudmundsson, G.; Grant, S. F. A.; Sveinbjornsdottir, S.; Valdimarsson, E. M.; Matthiasson, S. E.; Gudmundsdottir, O; Gurney, M.; Sainz, J.; Thorhallsdottir; Andresdottir, M.; Frigge, M. L.; Gudnason, V.; Kong, A.; Topol, E. J.; Thorgeirsson, G.; Gulcher, J. R.; Hakonarson, H.; Stefansson, K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 2004, 36, 233-239.
2. Helgadottir, A.; Manolescu, A.; Helgason, A.; Thorleifsson, G.; Thorsteinsdottir, U.; Gudbjartsson, D. F.; Gretarsdottir, S.; Magnusson, K. P.; Gudmundsson, G.; Hicks, A.; Jonsson, T.; Grant, S. F. A.; Sainz, J.; O'Brien, S. J.; Sveinbjornsdottir, S.; Valdimarsson, E. M.; Matthiasson, S. E.; Levey, A. I.; Abramson, J. L.; Reilly, M.; Vaccarino, V.; Wolfe, M.; Gudnason, V.; Quyyumi, A. A.; Topol, E. J.; Rader, D. J.; Thorgeirsson, G.; Gulcher, J. R.; Hakonarson, H.; Kong, A.; Stefansson, K. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 2006, 38, 68-74.
3. Meng, C. Q. Atherosclerosis is an inflammatory disorder after all. Curr. Top. Med. Chem 2006, 6, 93-102.
4. Spanbroek, R.; Grabner, R.; Lotzer, K.; Hildner, M.; Urbach, A.; Ruhling, K.; Moos, M. P.; Kaiser, B.; Cohnert, T. U.; Wahlers, T.; Zieske, A.; Plenz, G.; Robenek, H.; Salbach, P.; Kuhn, H.; Radmark, O.; Samuelsson, B.; Habenicht, A. J. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (3), 1238-1243.
5. Cipollone, F.; Mezzetti, A.; Fazia, M. L.; Cuccurullo, C.; Iezzi, A.; Ucchino, S.; Spigonardo, F.; Bucci, M.; Cuccurullo, F.; Prescott, S. M.; Stafforini, D. M. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1665-1670.
6. Qiu, H.; Gabrielsen, A.; Agardh, H. E.; Wan, M.; Wetterholm, A.; Wong, C. H.; Hedin, U.; Swedenborg, J.; Hansson, G. K.; Samuelsson, B.; Paulsson-Berne, G.; Haeggström, J. Z. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (21), 8161-8166.
7. (a) Lewis, R. A.; Austen, K. F.; Soberman, R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathology in human diseases. N. Engl. J. Med. 1990, 232, 645-655.
8. (b) Drazen, J. M.; Austen, K. F. Leukotrienes and airway responses. Am. Rev. Respir. Crit. Care Dis. 1987, 136, 985-998.
9. (c) Drazen, J. M. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997, 17, S22-S30.
10. (d) Marx, J. L. The leukotrienes in allergy and inflammation. Science 1982, 215, 1380-1383.
11. (e) Griffiths, R. J.; Pettipher, E. R.; Koch, K.; Farrell, C. A.; Breslow, R.; Conklyn, M. J.; Smith, M. A.; Hackman, B. C.; Wimberly, D. J.; Milici, A. J. Leukotriene B4 plays a critical role in the progression of collageninduced arthritis. Proc. Natl. Acad. Sci. U.S.A. 1995, 92 (2), 517-521.
12. (f) Shao, W. H.; Del, Prete, A.; Bock, C. B.; Haribabu, B. Targeted disruption of leukotriene B4 receptors BLT1 and BLT2: a critical role for BLT1 in collagen-induced arthritis in mice. J. Immunol. 2006, 176 (10), 6254-6261.
13. (g) Tsuji, F.; Oki, K.; Fujisawa, K.; Okahara, A.; Horiuchi, M.; Mita, S. Involvement of leukotriene B4 in arthritis models. Life Sci. 1999, 64 (3), PL51-PL56.
14. (h) Barnes, P. J. New treatments for COPD. Nat. Rev. Drug Discovery 2002, 1 (6), 437-446.
15. (i) Gompertz, S.; Stockley, R.A.Arandomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002 122 (1), 289-294.
16. (j) Lemiere, C.; Pelissier, S.; Tremblay, C.; Chaboillez, S.; Thivierge, M.; Stankova, J.; Rola-Pleszczynski, R. Leukotrienes and isocyanate-induced asthma: a pilot study. Clin. Exp. Allergy 2004, 34 (11), 1684-1689.
17. (k) Luster, A. D.; Tager, A. M. T-cell trafficking in asthma: lipid mediators grease the way. Nat. Rev. Immunol. 2004, 4 (9), 711-724.
18. (l) Terawaki, K.; Yokomizo, T.; Nagase, T.; Toda, A.; Taniguchi, M.; Hashizume, K..; et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2?type immune responses. J. Immunol. 2005, 175 (7), 4217-4225.
19. (m) Montuschi, P.; Sala, A.; Dahlen, S. E.; Folco, G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discovery Today 2007, 12 (9-10), 404-412.
20. (a) Brooks, D. W.; Summers, J. B.; Gunn, B. P.; Rodriques, K. E.; Martin, J. G.; Martin, M. B.; Mazdiyasni, H.; Holms, J. H.; Stewart, A. O.; Moore, J. L.; Young, P. R.; Albert, D. H.; Bouska, J. B.; Malo, P. E.; Dyer, R. D.; Bell, R. L.; Rubin, P.; Kesterson, J.; Carter, G. W. The discovery of A-64077, a clinical candidate for treating diseases involving leukotriene mediators. In Abstracts of the International Chemical Congress of Pacific Basin Societies; Honolulu, HI, 1989; BIOS 34 .
21. (b) Sirois, P.; Borgeat, P.; Lauziere, M.; Dube, L.; Rubin, P. R.; Kesterson, J. Effect of zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Agents Actions 1991, 34, 117-120.
22. Labelle, M.; Belley, M.; Gareau, Y.; Gauthier, J. Y.; Guay, D.; Gordon, R.; Grossman, S. G.; Jones, T. R.; Leblanc, Y.; McAuliffe, M.; McFarlane, C.; Masson, P.; Metters, K. M.; Ouimet, N.; Patrick, D. H.; Piechuta, H.; Rochette, C.; Sawyer, N.; Xiang, Y. B.; Pickett, C. B.; Ford-Hutchinson, A. W.; Zamboni, R. J.; Young, R. N. Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 1995, 5 (3), 283-288.
23. Matassa, V. G.; Maduskuie, T. P.; Shapiro,H. S.; Hesp, B.; Snyder, D. W.; Aharony, D.; Krell, R. D.; Keith, R. A. Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3,5-Substituted Indoles and Indazoles. J. Med. Chem. 1990, 33, 1781-1790.
24. Samuelsson, B.; Funk, C. D. Enzymes involved in the biosynthesis of leukotriene B4. J. Biol. Chem. 1989, 264, 19469-19472.
25. (a) Lewis, R. A.; Austen, K. F.; Soberman, R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathology in human diseases. N. Engl. J. Med. 1990, 232, 645-655.
26. (b) Werz, O.; Steinhilber, D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 2006, 112, 701-718.
27. Mitsunobu, F.; Mifune, T.; Hosaki, Y.; Ashida, K.; Tsugeno, H.; Okamoto, M.; Takata, S.; Tanizaki, Y. Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2001, 107, 492-498.
28. 4 hydrolase in peripheral leukocytes of patients with atopic dermatitis. Arch. Dermatol. Res. 1996, 288, 168-172.
29. Klickstein, L. B.; Shapleigh, C.; Geotzl, E. J. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J. Clin. Invest. 1980, 66, 1166-1170.
30. (a) Penning, T. D.; Askonas, L. J.; Djuric, S. W.; Haack, R. A.; Yu, S. S.; Michener, M. L.; Krivi, G. G.; Pyla, E. Y. Kelatorphan and related analogs: Potent and selective inhibitors of leukotriene A4 hydrolase. Bioorg. Med. Chem. Lett. 1995, 5, 2517-2522.
31. (b) Hogg, J. H.; Ollmann, I. R.; Haeggström, J. Z.; Wetterholm, A.; Samuelsson, B.; Wong, C. H. Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase. Bioorg. Med. Chem. Lett. 1995, 3, 1405-1415.
32. (c) Tsuji, F.; Miyake, Y.; Enomoto, H.; Horiuchi, M.; Mita, S. Effects of SA6541, a leukotriene A4 hydrolase inhibitor, and indomethacin on carrageenan-induced murine dermatitis. Eur. J. Pharmacol. 1998, 346, 81-85.
33. (d) Grice, C. A.; Tays, K. L.; Savall, B. M.;Wei, J.; Butler,C. R.; Axe, F. U.; Bembenek, S. D.; Fourie, A. M.; Dunford, P. J.; Lundeen, K.; Coles, F.; Xue, X.; Riley, J. P.; Williams, K. N.; Karlsson, L.; Edwards, J. P. J. Med. Chem. 2008, 51, 4150-4169.
34. (e) Rao, N. L.; Dunford, P. J.; Xue, X.; Jiang, X.; Lundeen, K. A.; Coles, F.; Riley, J. P.; Williams, K. N.; Grice, C. A.; Edwards, J. P.; Karlsson, L.; Fourie, A. M. J. Pharmacol. Exp. Ther. 2007, 321, 1154-1160.
35. (f) Khim, S. K.; Bauman, J.; Evans, J.; Freeman, B.; King, B.; Kirkland, T.; Kochanny, M.; Lentz, D.; Liang, A.; Mendoza, L.; Phillips, G.; Tseng, J. L.; Wei, R. G.; Ye, H.; Yu, L.; Parkinson, J.; Guilford, W. J. Bioorg. Med. Chem. Lett. 2008, 18, 3895-3898.
36. (g) Kirkland, T. A.; Adler, M.; Bauman, J. G.; Chen, M.; Haeggstrom, J. Z.; King, B.; Kochanny,M. J.; Liang, A. M.; Mendoza, L.; Phillips, G. B.; Thunnissen, M.; Trinh, L.; Whitlow, M.;Ye, B.;Ye, H.; Parkinson, J.; Guilford,W. J. Bioorg. Med. Chem. 2008, 16, 4963-4983.
37. (h) Ye, B.; Bauman, J.; Chen, M.; Davey, D.; Khim, S. K.; King, B.; Kirkland, T.; Kochanny, M.; Liang, A.; Lentz, D.; May, K.; Mendoza, L.; Phillips, G.; Selchau, V.; Schlyer, S.; Tseng, J. L.; Wei, R. G.; Ye, H.; Parkinson, J.; Guilford, W. J. Bioorg. Med. Chem. Lett. 2008, 18, 3891-3894.
38. (i) Enomoto, H.; Morikawa, Y.; Miyake, Y.; Tsuji, F.; Mizuchi, M.; Suhara, H.; Fujimura, K.; Horiuchi, M.; Ban, M. Bioorg. Med. Chem. Lett. 2009, 19, 442-446.
39. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51, 3661-3689.
40. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragmentbased lead discovery. Nat. Rev. Drug Discovery 2004, 3, 660-672.
41. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "rule of three" for fragment-based lead discovery? Drug Discovery. Today 2003, 8, 876-877.
42. Nienaber, V. L.; Greer, J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 2000, 18, 1105-1108.
43. Hopkins, A. L.; Colin, R.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
44. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery. Drug Discovery Today 2005, 10, 464-469.
45. Oprea, T.; Allu, T. R.; Fara, D. C.; Rad, R. F.; Ostopovici, L.; Bologa, C. G. Lead-like, drug-like or "Pub-like": how different are they? J. Comput.-Aided Des. 2007, 21, 113-119.
46. Davies, D.; Mamat, B.; Magnusson, O.; Christensen, J.; Haraldsson, M.; Mishra, R.; Pease, B.; Hansen, E.; Singh, J.; Zembower, D.; Kim, H.; Kiselyov, A.; Burgin, A.; Gurney, M.; Stewart, L. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallograph. J. Med. Chem. 2009, 52, 4694-4715.
47. (a) Thunnissen, M. M.; Nordlund, P.; Haeggstrom, J. Z. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat. Struct. Biol. 2001, 8, 131-135.
48. (b) Thunnissen, M. M.; Andersson, G. M.; Samuelsson, B.; Wong, B.; Haeggström, C. H.; Crystal, J. Z. Structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 2002, 16, 1648-1650.
49. Penning, T. D.; Chandrakumar, N. Z; Chen, B. B; Chen, H. Y.; Desai, B. N.; Djuric, S. W.; Docter, S. H.; Gasiecki, A. F.; Haack, R. A.; Miyashiro, J. M.; Russell, M. A. Structure-activity relationship studies on 1-[2-(4-phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase. J. Med. Chem. 2002, 43, 721-735.
50. 4Hfar from the active site (see ref 21), was used as reference for unligated active site topology.
51. Cerep; http://www.cerep.fr/cerep/users/pages/catalog/Profiles/catalog. asp.
52. Such a transformation has in fact been reported for SC-57461. Yuan, J. H.; Birkmeier, J.; Yang, D. C.; Hribar, J. D.; Liu, N.; Bible, R.; Hajdu, E.; Rock, M.; Schoenhard, G. Isolation and identification of metabolites of leukotriene A4 hydrolase inhibitor SC-57461 in rats. Drug Metab. Dispos. 1996, 24, 1124-1133.
53. Yan, Z.; Caldwell, G. W. Metabolism profiling and cytochrome P450 inhibition and induction. Drug Discovery Curr. Top. Med. Chem. 2001, 1, 403-425.
54. (a) Mitsunobu, O.; Yamada, M. Bull. Chem. Soc. Jpn. 1967, 40, 2380-2382.
55. (b) Mitsunobu, O. Synthesis 1981, 1-28.
56. Wolfe, J. P.; Buchwald, S. L. Palladium-catalyzed amination of aryl iodides. J. Org. Chem. 1996, 61, 1133-1135.
57. Gandolfi, C. A.; Di-Domenico, R.; Spinelli, S.; Gallico, L.; Fiocchi, L.; Lotto, A.; Menta, E.; Borghi, A.; Rosa, C. D.; Tognella, S. N-Acyl-2-substituted-1,3-thiazolidineas, new class of non-narcotic antitussive agents: Studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-3-oxothiazolidine-3-propanoate. J. Med. Chem. 1995, 38, 508-525.
58. Tagat, T.; Nishida, M. Palladium charcol-catlysed Suzuki-Miyaura coupling to obatin arylpyridines and arylquinolines. J. Org. Chem. 2003, 68, 9412-9415.
59. Ma, D.; Qian, C. N,N-Dimethyl glycine-promoted Ullmann coupling reaction of phenols and aryl halides. Org. Lett. 2003, 5 (21), 3799-3802.